Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/051108external-prioritypatent/WO2010029335A1/en
Application filed by Astrazeneca Ab, Pozen IncfiledCriticalAstrazeneca Ab
Publication of TN2011000096A1publicationCriticalpatent/TN2011000096A1/en
The present disclosure is directed to the use of naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition in unit dose form, wherein said esomeprazole, or pharmaceutically acceptable salt thereof, is released from said unit dose form at a specified pH, wherein one unit dose form is for administration as an AM dose and a second unit dose form is for administration about 10 hours later as a PM dose to target a specified pharmacokinetic profile.
TN2011000096A2009-09-032011-02-25Method for delivering a pharmaceutical composition to patient in need thereof
TN2011000096A1
(en)
Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment